CINXE.COM
<!DOCTYPE html> <html lang="en"> <head id="Head1"><meta charset="utf-8" /><title> </title><link href="../../../Content/Site.css" rel="stylesheet" /><link href="../../../Content/bootstrap-3.3.2-dist/css/bootstrap.min.css" rel="stylesheet" /><link href="../../../Content/bootstrap-3.3.2-dist/css/bootstrap.icon-large.min.css" rel="stylesheet" /><link href="//maxcdn.bootstrapcdn.com/font-awesome/4.3.0/css/font-awesome.min.css" rel="stylesheet" /><link href="../../../Content/Custom.css" rel="stylesheet" /><link href="../../Content/CustomSubPage.css" rel="stylesheet" /><link href="../../favicon.ico" rel="shortcut icon" type="image/x-icon" /> <script src="/Scripts/modernizr-2.5.3.js"></script> <meta name="viewport" content="width=device-width" /> <script type="text/javascript" src="http://www.jcnnewswire.com/jquery/jquery-latest.min.js"> </script> <script type="text/javascript" src="http://www.jcnnewswire.com/jquery/jquery.fancybox.pack.js?v=2.1.5"></script> <link rel="stylesheet" type="text/css" href="http://www.jcnnewswire.com/jquery/jquery.fancybox.css?v=2.1.5" media="screen"> <style> .lang li { display:inline; } .lang a { color:#fff; } </style> </head> <body> <form method="post" action="./Medicine" onsubmit="javascript:return WebForm_OnSubmit();" id="Form1"> <div class="aspNetHidden"> <input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="" /> <input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" /> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="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" /> </div> <script type="text/javascript"> //<![CDATA[ var theForm = document.forms['Form1']; if (!theForm) { theForm = document.Form1; } function __doPostBack(eventTarget, eventArgument) { if (!theForm.onsubmit || (theForm.onsubmit() != false)) { theForm.__EVENTTARGET.value = eventTarget; theForm.__EVENTARGUMENT.value = eventArgument; theForm.submit(); } } //]]> </script> <script src="/WebResource.axd?d=YcG_1mlPARhRW7O4sA9bWHA-qI2d_t_BO06OeFBhoaiREhheyXs3-1psdTUSDOHCoQeBPKlq2r8vu_cSQNfig-Is-AxTXJhRKwfH8V2oM9c1&t=638611161180000000" type="text/javascript"></script> <script src="/WebResource.axd?d=bIpPyEdzAMer_bwfyhWa6rFaO8WGfxnN2PvV0BTsVTDvSo40Rw6pGSZlPV1TZTu152c0lKoeiKGVeRIzWI8ylmApYjdRpTU999mo98-2hDs1&t=638611161180000000" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ function WebForm_OnSubmit() { if (typeof(ValidatorOnSubmit) == "function" && ValidatorOnSubmit() == false) return false; return true; } //]]> </script> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="3FCCA5B3" /> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAAjtui2EgSUg+3RPb9za72/UsK8Qcg6x7YEKBpnNUn26Cy8zACrOsmKsedR3ZCAsXqOGS+DzgQFV1SKQgnQsG6cp7CLa1fUEIk/qLK4P6vyiKZQmGa9TupdzyO7LwN2u6MTQEUl6WGnBNfQmSTEu9ta3KvtM4vD/EUF5LtATB5mUYqDYM+HZDD/GcOv9hf4oEL3pgRnrET31idlN7ylJ2iVg" /> </div> <header> <div style="background-color:#000;"> <div class="content-wrapper"> <div style="color:#fff;padding-bottom:22px;"> <span style="float:right;"> <ul class="lang"> <li style="font-size:12px;color:#ABA9A9;"> <a href="/"> TOPページ</a> </li> <li style="font-size:12px;color:#ABA9A9;">|</li> <li style="font-size:12px;color:#ABA9A9;"> <a href="/english/"> 英語</a> </li> <li style="font-size:12px;color:#ABA9A9;"> </li> <li style="font-size:12px;color:#ABA9A9;background-color: #E55657; padding-top: 8px; padding-bottom: 4px; padding-left: 3px;"><a href="/japanese/"> 日本語</a></li> <li style="font-size:12px;color:#ABA9A9;"> | </li> <li style="font-size:12px;color:#fff;"> CONNECT WITH US:</li> <li class="nolink"> <a href="https://www.facebook.com/jcnnewswire" target="_blank" class="social"> <i class="fa fa-facebook-square"></i></a> </li> <li class="nolink"> <a href="https://twitter.com/JCNNewswire" target="_blank" class="social"><i class="fa fa-twitter-square"></i></a> </li> <li class="nolink"> <a href="/japanese/rssfeed/" class="social"><i class="fa fa-rss-square"></i></a> </li> </ul> </span> </div> </div> </div> <br /> <div class="content-wrapper"> <div class="feature-float-left"> <p class="site-title"><a href="../../" id="A1"> <img src="/Images/JCN-Newswire.jpg" width="300px"/></a></p> </div> <div class="float-right"> <section id="login"> <ul> </ul> <ul class="the-icons"> </ul> </section> </div> <div class="row"> <div class="col-md-12 col-md-12-nav"> <nav class="topnav"> <ul class="nav nav-tabs"> <li role="presentation"><a href="../../" id="A3">ホーム </a></li> <li role="presentation"><a href="../../About/" id="A4">JCNについて</a></li> <li role="presentation"><a href="../../Services/" id="A11">サービス</a></li> <li role="presentation"><a href="../../Contact/" id="A5">お問い合わせ</a></li> <li role="presentation"><a href="https://www.jcnnewswire.com/client/" id="A6">会員企業ログイン</a></li> <li style="padding-top:5px;"> <span id="RequiredFieldSearch" style="color:White;visibility:hidden;">*</span> <input name="ctl00$searchstring" type="text" id="searchstring" placeholder="キーワードで検索" style="width:150px;height:30px;font-size:14px;" /><input type="submit" name="ctl00$SearchButton" value="Go!" onclick="javascript:WebForm_DoPostBackWithOptions(new WebForm_PostBackOptions("ctl00$SearchButton", "", true, "", "", false, false))" id="SearchButton" class="btn btn-default" type="submit" style="height:30px;font-size: 13px;margin-left:2px;background-color:#f2f2f2;border-color:#ccc;" /> </li> </ul> </nav> </div> </div> </div> </header> <div id="body"> <section class="content-wrapper main-content clear-fix"> <ol class="breadcrumb"> <li><a href="/japanese/">ホーム</a></li> <li class="active">業種リリース</li> </ol> <hgroup class="title"> <h1> 健康・医薬品 プレスリリース</h1> </hgroup> <hr /> <div class="col-md-9"> <table id="MainContent_IndustryDataList" cellspacing="0" style="border-collapse:collapse;"> <tr> <td> <table cellpadding="2" cellspacing="0" class="Item"> <tr valign="top"> <td class="header"> <img title="Newton Biocapital" src="http://www.jcnnewswire.com/image/toppage/NewtonBiocapital_55.jpg"><br /> <a href="/japanese/pressrelease/93852/3/ニュートン-バイオキャピタル、⽇本の創薬スタートアップのテンセグリティファーマに対し、第-2-号ファンドより、⽇本初の投資を発表" class="newslink"> ニュートン バイオキャピタル、⽇本の創薬スタートアップのテンセグリティファーマに対し、第 2 号ファンドより、⽇本初の投資を発表</a> <br /> <span class="note"> Nov 14, 2024 11:00 JST </span> <br /> <div class="body"> ⽇本および欧州の創薬スタートアップ企業への投資と育成を⽬的としたベンチャーキャピタルのニュートン バイオキャピタル（本社:ベルギー、ブリュッセル、CEO:アラン・パルトゥーンス、⽇本代表：鈴⽊貞史、以下、NBC）は、本⽇、2021 年に設⽴したファンド「Newton Biocapital Partners II（NBC II）」より、⽇本の創薬スタートアップであるテンセグリティファーマ株式会社（本社：東京都中央区、創業者：代表取締役 CEO：中原崇⼈）に対し、⽇本における最初の投資を⾏うことを発表しました。 <br /> <span class="note"><a href="/japanese/pressrelease/93852/3/ニュートン-バイオキャピタル、⽇本の創薬スタートアップのテンセグリティファーマに対し、第-2-号ファンドより、⽇本初の投資を発表" class="newslink">More info..</a></span> </div> <td> </td> </tr> <tr><td colspan="2"><hr style="border-top:1px solid #ccc;"/></td></tr> </table> </td> </tr><tr> <td> <table cellpadding="2" cellspacing="0" class="Item"> <tr valign="top"> <td class="header"> <img title="Newton Biocapital" src="http://www.jcnnewswire.com/image/toppage/NewtonBiocapital_55.jpg"><br /> <a href="/japanese/pressrelease/93852/3/ニュートン-バイオキャピタル、⽇本の創薬スタートアップのテンセグリティファーマに対し、第-2-号ファンドより、⽇本初の投資を発表" class="newslink"> ニュートン バイオキャピタル、⽇本の創薬スタートアップのテンセグリティファーマに対し、第 2 号ファンドより、⽇本初の投資を発表</a> <br /> <span class="note"> Nov 14, 2024 11:00 JST </span> <br /> <div class="body"> ⽇本および欧州の創薬スタートアップ企業への投資と育成を⽬的としたベンチャーキャピタルのニュートン バイオキャピタル（本社:ベルギー、ブリュッセル、CEO:アラン・パルトゥーンス、⽇本代表：鈴⽊貞史、以下、NBC）は、本⽇、2021 年に設⽴したファンド「Newton Biocapital Partners II（NBC II）」より、⽇本の創薬スタートアップであるテンセグリティファーマ株式会社（本社：東京都中央区、創業者：代表取締役 CEO：中原崇⼈）に対し、⽇本における最初の投資を⾏うことを発表しました。 <br /> <span class="note"><a href="/japanese/pressrelease/93852/3/ニュートン-バイオキャピタル、⽇本の創薬スタートアップのテンセグリティファーマに対し、第-2-号ファンドより、⽇本初の投資を発表" class="newslink">More info..</a></span> </div> <td> </td> </tr> <tr><td colspan="2"><hr style="border-top:1px solid #ccc;"/></td></tr> </table> </td> </tr><tr> <td> <table cellpadding="2" cellspacing="0" class="Item"> <tr valign="top"> <td class="header"> <img title="Eisai" src="http://www.jcnnewswire.com/image/toppage/eisai45.jpg"><br /> <a href="/japanese/pressrelease/93171/3/エーザイ、痛風・高尿酸血症治療剤「URECE(R)-Tablets」（一般名：ドチヌラド）についてタイで承認を取得" class="newslink"> エーザイ、痛風・高尿酸血症治療剤「URECE(R) Tablets」（一般名：ドチヌラド）についてタイで承認を取得</a> <br /> <span class="note"> Oct 08, 2024 13:00 JST </span> <br /> <div class="body"> エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、痛風・高尿酸血症治療剤「URECE(R) Tablets」（一般名：ドチヌラド）について、タイにおいて「痛風、高尿酸血症」の適応で承認を取得したことをお知らせします。 <br /> <span class="note"><a href="/japanese/pressrelease/93171/3/エーザイ、痛風・高尿酸血症治療剤「URECE(R)-Tablets」（一般名：ドチヌラド）についてタイで承認を取得" class="newslink">More info..</a></span> </div> <td> </td> </tr> <tr><td colspan="2"><hr style="border-top:1px solid #ccc;"/></td></tr> </table> </td> </tr><tr> <td> <table cellpadding="2" cellspacing="0" class="Item"> <tr valign="top"> <td class="header"> <img title="CNN" src="http://www.jcnnewswire.com/image/toppage/cnn25.jpg"><br /> <a href="/japanese/pressrelease/93150/3/CNNが人々の生活をつなぐ医療の未来を探る特別番組「Tomorrow-Transformed」を放送" class="newslink"> CNNが人々の生活をつなぐ医療の未来を探る特別番組「Tomorrow Transformed」を放送</a> <br /> <span class="note"> Oct 04, 2024 19:00 JST </span> <br /> <div class="body"> 医療の黎明期から、テクノロジーは医療システムやサービスを飛躍的に進化させ、私たちがより長く、より質の高い生活を送るための支えとなっています。30分の特別番組「Tomorrow Transformed」では、医療分野における連携やパートナーシップ、コラボレーションを、人間味あふれる一人称の物語を通じて探ります。 <br /> <span class="note"><a href="/japanese/pressrelease/93150/3/CNNが人々の生活をつなぐ医療の未来を探る特別番組「Tomorrow-Transformed」を放送" class="newslink">More info..</a></span> </div> <td> <table width="210" class="topimg" style="border:1px solid #ccc;text-align:center;"><tr><td><a id="single_1" href="https://photos.acnnewswire.com/20241004.CNN1.jpg"><img src="https://photos.acnnewswire.com/20241004.CNN1.jpg" width="240px"></a></td></tr></table> </td> </tr> <tr><td colspan="2"><hr style="border-top:1px solid #ccc;"/></td></tr> </table> </td> </tr><tr> <td> <table cellpadding="2" cellspacing="0" class="Item"> <tr valign="top"> <td class="header"> <img title="CNN" src="http://www.jcnnewswire.com/image/toppage/cnn25.jpg"><br /> <a href="/japanese/pressrelease/93150/3/CNNが人々の生活をつなぐ医療の未来を探る特別番組「Tomorrow-Transformed」を放送" class="newslink"> CNNが人々の生活をつなぐ医療の未来を探る特別番組「Tomorrow Transformed」を放送</a> <br /> <span class="note"> Oct 04, 2024 19:00 JST </span> <br /> <div class="body"> 医療の黎明期から、テクノロジーは医療システムやサービスを飛躍的に進化させ、私たちがより長く、より質の高い生活を送るための支えとなっています。30分の特別番組「Tomorrow Transformed」では、医療分野における連携やパートナーシップ、コラボレーションを、人間味あふれる一人称の物語を通じて探ります。 <br /> <span class="note"><a href="/japanese/pressrelease/93150/3/CNNが人々の生活をつなぐ医療の未来を探る特別番組「Tomorrow-Transformed」を放送" class="newslink">More info..</a></span> </div> <td> <table width="210" class="topimg" style="border:1px solid #ccc;text-align:center;"><tr><td><a id="single_1" href="https://photos.acnnewswire.com/20241004.CNN1.jpg"><img src="https://photos.acnnewswire.com/20241004.CNN1.jpg" width="240px"></a></td></tr></table> </td> </tr> <tr><td colspan="2"><hr style="border-top:1px solid #ccc;"/></td></tr> </table> </td> </tr><tr> <td> <table cellpadding="2" cellspacing="0" class="Item"> <tr valign="top"> <td class="header"> <img title="Eisai" src="http://www.jcnnewswire.com/image/toppage/eisai45.jpg"><br /> <a href="/japanese/pressrelease/93114/3/エーザイ、サウジアラビアの医薬品販売子会社が事業活動を開始" class="newslink"> エーザイ、サウジアラビアの医薬品販売子会社が事業活動を開始</a> <br /> <span class="note"> Oct 02, 2024 11:00 JST </span> <br /> <div class="body"> エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、サウジアラビア王国（以下、サウジアラビア）のリヤドに設立した医薬品販売会社「Eisai Pharmaceuticals Single Person Limited Liability Company」（以下、エーザイ・サウジアラビア）が本格稼働し、事業活動を開始したことをお知らせします。 <br /> <span class="note"><a href="/japanese/pressrelease/93114/3/エーザイ、サウジアラビアの医薬品販売子会社が事業活動を開始" class="newslink">More info..</a></span> </div> <td> </td> </tr> <tr><td colspan="2"><hr style="border-top:1px solid #ccc;"/></td></tr> </table> </td> </tr><tr> <td> <table cellpadding="2" cellspacing="0" class="Item"> <tr valign="top"> <td class="header"> <img title="China Medical System Holdings Ltd." src="http://www.jcnnewswire.com/image/toppage/CMS_Top.jpg"><br /> <a href="/japanese/pressrelease/92990/3/China-Medical-System:-New-Drug-Application-for-Vitiligo-Indication-of-Ruxolitinib-Phosphate-Cream-Ac" class="newslink"> China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China</a> <br /> <span class="note"> Sep 24, 2024 22:00 JST </span> <br /> <div class="body"> China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). <br /> <span class="note"><a href="/japanese/pressrelease/92990/3/China-Medical-System:-New-Drug-Application-for-Vitiligo-Indication-of-Ruxolitinib-Phosphate-Cream-Ac" class="newslink">More info..</a></span> </div> <td> </td> </tr> <tr><td colspan="2"><hr style="border-top:1px solid #ccc;"/></td></tr> </table> </td> </tr><tr> <td> <table cellpadding="2" cellspacing="0" class="Item"> <tr valign="top"> <td class="header"> <img title="China Medical System Holdings Ltd." src="http://www.jcnnewswire.com/image/toppage/CMS_Top.jpg"><br /> <a href="/japanese/pressrelease/92990/3/China-Medical-System:-New-Drug-Application-for-Vitiligo-Indication-of-Ruxolitinib-Phosphate-Cream-Ac" class="newslink"> China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China</a> <br /> <span class="note"> Sep 24, 2024 22:00 JST </span> <br /> <div class="body"> China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). <br /> <span class="note"><a href="/japanese/pressrelease/92990/3/China-Medical-System:-New-Drug-Application-for-Vitiligo-Indication-of-Ruxolitinib-Phosphate-Cream-Ac" class="newslink">More info..</a></span> </div> <td> </td> </tr> <tr><td colspan="2"><hr style="border-top:1px solid #ccc;"/></td></tr> </table> </td> </tr><tr> <td> <table cellpadding="2" cellspacing="0" class="Item"> <tr valign="top"> <td class="header"> <img title="Ainos, Inc" src="http://www.jcnnewswire.com/image/toppage/Ainos68.jpg"><br /> <a href="/japanese/pressrelease/92981/3/Ainos、限られた治療法しかない希少疾患シェーグレン症候群に対するVELDONAの台湾臨床試験開始計画を発表" class="newslink"> Ainos、限られた治療法しかない希少疾患シェーグレン症候群に対するVELDONAの台湾臨床試験開始計画を発表</a> <br /> <span class="note"> Sep 24, 2024 18:00 JST </span> <br /> <div class="body"> Ainos, Inc.（NASDAQ:AIMD、NASDAQ:AIMDW、以下「Ainos」または「当社」）は、最先端のAI駆動型ポイントオブケアテスト（POCT）および低用量インターフェロン療法に特化した革新的なヘルスケア企業として、台湾においてVELDONA(R)（非常に低用量インターフェロンα）を用いたシェーグレン症候群の治療に関する臨床試験を台北医科大学双和病院にて実施する計画を発表いたします。 <br /> <span class="note"><a href="/japanese/pressrelease/92981/3/Ainos、限られた治療法しかない希少疾患シェーグレン症候群に対するVELDONAの台湾臨床試験開始計画を発表" class="newslink">More info..</a></span> </div> <td> </td> </tr> <tr><td colspan="2"><hr style="border-top:1px solid #ccc;"/></td></tr> </table> </td> </tr><tr> <td> <table cellpadding="2" cellspacing="0" class="Item"> <tr valign="top"> <td class="header"> <img title="Ainos, Inc" src="http://www.jcnnewswire.com/image/toppage/Ainos68.jpg"><br /> <a href="/japanese/pressrelease/92981/3/Ainos、限られた治療法しかない希少疾患シェーグレン症候群に対するVELDONAの台湾臨床試験開始計画を発表" class="newslink"> Ainos、限られた治療法しかない希少疾患シェーグレン症候群に対するVELDONAの台湾臨床試験開始計画を発表</a> <br /> <span class="note"> Sep 24, 2024 18:00 JST </span> <br /> <div class="body"> Ainos, Inc.（NASDAQ:AIMD、NASDAQ:AIMDW、以下「Ainos」または「当社」）は、最先端のAI駆動型ポイントオブケアテスト（POCT）および低用量インターフェロン療法に特化した革新的なヘルスケア企業として、台湾においてVELDONA(R)（非常に低用量インターフェロンα）を用いたシェーグレン症候群の治療に関する臨床試験を台北医科大学双和病院にて実施する計画を発表いたします。 <br /> <span class="note"><a href="/japanese/pressrelease/92981/3/Ainos、限られた治療法しかない希少疾患シェーグレン症候群に対するVELDONAの台湾臨床試験開始計画を発表" class="newslink">More info..</a></span> </div> <td> </td> </tr> <tr><td colspan="2"><hr style="border-top:1px solid #ccc;"/></td></tr> </table> </td> </tr> </table> <nav> <ul class="pagination"> <li> <a onclick="return false;" id="MainContent_rptPager_lnkPage_0" class="page_disabled1" href="javascript:__doPostBack('ctl00$MainContent$rptPager$ctl00$lnkPage','')">1</a> </li> <li> <a id="MainContent_rptPager_lnkPage_1" class="page_enabled1" href="javascript:__doPostBack('ctl00$MainContent$rptPager$ctl01$lnkPage','')">2</a> </li> <li> <a id="MainContent_rptPager_lnkPage_2" class="page_enabled1" href="javascript:__doPostBack('ctl00$MainContent$rptPager$ctl02$lnkPage','')">3</a> </li> <li> <a id="MainContent_rptPager_lnkPage_3" class="page_enabled1" href="javascript:__doPostBack('ctl00$MainContent$rptPager$ctl03$lnkPage','')">>></a> </li> <li> <a id="MainContent_rptPager_lnkPage_4" class="page_enabled1" href="javascript:__doPostBack('ctl00$MainContent$rptPager$ctl04$lnkPage','')">Last</a> </li> </ul> </nav> </div> <div class="col-md-3"> <div class="featuredHead"> 業種 </div> <span id="MainContent_SectorList_SectorList"><table id="masterdiv" class="table table-bordered"><tr><td><a href="/japanese/industrynews/186/ビジネス" class="newslink">ビジネス</td></tr><tr><td><a href="/japanese/industrynews/10/コミュニケーション" class="newslink">コミュニケーション</td></tr><tr><td><a href="/japanese/industrynews/256/CryptoCurrency" class="newslink">CryptoCurrency</td></tr><tr><td><a href="/japanese/industrynews/14/ファイナンシャル" class="newslink">ファイナンシャル</td></tr><tr><td><a href="/japanese/industrynews/16/産業" class="newslink">産業</td></tr><tr><td><a href="/japanese/industrynews/24/消費財" class="newslink">消費財</td></tr><tr><td><a href="/japanese/industrynews/18/健康・医薬品" class="newslink">健康・医薬品</td></tr><tr><td><a href="/japanese/industrynews/12/持続可能性" class="newslink">持続可能性</td></tr><tr><td><a href="/japanese/industrynews/11/テクノロジー" class="newslink">テクノロジー</td></tr></table></span> </div> <script type="text/javascript"> $(document).ready(function () { $("#single_1").fancybox({ helpers: { title: { type: 'float' } } }); }); </script> </section> </div> <footer> <div class="content-wrapper"> <div align="center"> Copyright © 2024 - JCN Newswire <div class="botton-nav"> <ul> <li><a href="../../" id="A7">ホムペジー</a></li> <li><a href="../../about/" id="A8">JCNについて</a></li> <li><a href="../../contact/" id="A9">お問い合わせ</a></li> <li><a href="../../rssfeed/" id="A10">RSS</a></li> <li><a href="../../Privacy/" id="A12">プライバシー ポリシー</a></li> <li><a href="../../Terms/" id="A13">免責事項</a></li> <li> - </li> <li class="nolink"> <a href="https://www.facebook.com/jcnnewswire" target="_blank" class="social"> <i class="fa fa-facebook-square"></i></a> </li> <li class="nolink"> <a href="https://twitter.com/JCNNewswire" target="_blank" class="social"><i class="fa fa-twitter-square"></i></a> </li> <li class="nolink"> <a href="/rssfeed/" class="social"><i class="fa fa-rss-square"></i></a> </li> </ul> </div> </div> </div> </footer> <script type="text/javascript"> //<![CDATA[ var Page_Validators = new Array(document.getElementById("RequiredFieldSearch")); //]]> </script> <script type="text/javascript"> //<![CDATA[ var RequiredFieldSearch = document.all ? document.all["RequiredFieldSearch"] : document.getElementById("RequiredFieldSearch"); RequiredFieldSearch.controltovalidate = "searchstring"; RequiredFieldSearch.errormessage = "*"; RequiredFieldSearch.evaluationfunction = "RequiredFieldValidatorEvaluateIsValid"; RequiredFieldSearch.initialvalue = ""; //]]> </script> <script type="text/javascript"> //<![CDATA[ var Page_ValidationActive = false; if (typeof(ValidatorOnLoad) == "function") { ValidatorOnLoad(); } function ValidatorOnSubmit() { if (Page_ValidationActive) { return ValidatorCommonOnSubmit(); } else { return true; } } //]]> </script> </form> <script> (function (i, s, o, g, r, a, m) i['GoogleAnalyticsObject'] = r; i[r] = i[r] || function () (i[r].q = i[r].q || []).push(arguments) }, i[r].l = 1 * new Date(); a = s.createElement(o), m = s.getElementsByTagName(o)[0]; a.async = 1; a.src = g; m.parentNode.insertBefore(a, m) })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga'); ga('create', 'UA-61831624-1', 'auto'); ga('send', 'pageview'); </script> </body> </html>